MADRID--(BUSINESS WIRE)--MedLumics, a medical imaging diagnostics company specializing in advanced optical coherence tomography (OCT) technology, has announced the appointment of industry expert Dr. Wolfgang Reim as independent director of its board. Currently a member of the company’s Scientific Advisory Board, Dr. Reim will use his role as independent director to consult on strategic decisions related to product portfolio development, corporate growth and business opportunities.
“Wolfgang’s experience in creating, developing and commercializing medical technology, his global vision of the medical imaging market, and his proven strategic skills will help us optimize the potential of MedLumics’ technology innovation to deliver clinical value to physicians and patients around the world,” said Eduardo Margallo, president and co-founder of MedLumics. “We expect him to play a pivotal role in the launch of our first clinical application, which will allow for the high-resolution evaluation of skin lesions.”
Dr. Reim brings valuable experience to MedLumics, having served in a range of executive leadership positions at leading medical technology companies. He was the chief executive officer at Dräger Medical AG & Co. KG and a member of the board of directors at Drägerwerk AG for seven years. Previously, he was president of the Ultrasound Division at Siemens Healthcare, based in the United States, and also held top executive positions in areas such as magnetic resonance imaging, mammography, urology, lithotripsy, surgery, portable X-rays and accessories. At the beginning of his career, Reim worked at the R&D centers of IBM and Siemens. Currently, he is a member of the board of directors at Carl Zeiss Meditec AG, GN Store Nord A/S, Ondal Medical Systems and Elekta AB.
“MedLumics is building a singular non-invasive imaging platform based on integrated optics with the potential to transform clinical practice in important areas including dermatology, cardiology and surgery. It is a pleasure for me to accept the position of independent director and help the company become a recognized player in the medical technology industry,” said Dr. Reim. “I am convinced that together we are going to improve the standard of care for millions of patients worldwide by providing them with more efficient and effective medical diagnostic solutions.”
MedLumics has developed OCT imaging technology that integrates all optical and electrical components in a compact microchip-based system that can that can produce dynamic, real-time, high-resolution diagnostic images with a tissue penetration capability of up to two millimeters. The proprietary technology is designed to allow physicians to perform a non-invasive optical “digital biopsy” of tissues that avoids damage to vulnerable structures, reduces procedure time, and eliminates the invasiveness of conventional biopsy tissue sample extraction.
Founded in 2009, MedLumics is a medical imaging diagnostics company specializing in advanced optical coherence tomography (OCT) technology. Its proprietary platform technology integrates optical and electrical components in a compact microchip-based OCT system that can produce dynamic, real-time, high-resolution diagnostic images that allow physicians to perform a non-invasive optical “digital biopsy” of tissues. MedLumics received a 3.5 million Euro/4.7 million USD Series A financing from joint investors Ysios Capital Partners and “la Caixa” (through Caixa Capital Risc) in November 2011.
For more information, visit www.medlumics.com.